Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | ATM | Q13315 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843924 | 1.00 | CTSS (0.52) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL191987 | 1.00 | CTSS (0.52) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL11355325 | 0.94 | CTSS (0.54) | CTSSCTSKFOLH1NAALAD2MIF | |
| Water SCHEMBL11354350 | 0.93 | CTSS (0.56) | CTSSCTSKFOLH1NAALAD2MIF | |
| Water SCHEMBL11354352 | 0.93 | CTSS (0.56) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL11352435 | 0.89 | CTSS (0.46) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL11353497 | 0.89 | CTSS (0.46) | CTSSCTSKFOLH1NAALAD2MIF | |
| SCHEMBL15962588 | 0.88 | CTSS (0.49) | CTSSCTSKMIFPPARAATM | |
| SCHEMBL8513252 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAATMPPARG | |
| SCHEMBL12195416 | 0.88 | CTSS (0.52) | CTSSCTSKPPARAATMPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090173-A1 | MODIFIED SELF-IMMOLATING MOIETIES IN ANTIBODY-DRUG CONJUGATES | CODEABLE THERAPEUTICS, INCORPORATED (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20250114374-A1 | BCL-2 INHIBITORS | NEWAVE PHARMACEUTICAL INC. | 2025-04-10 | — | — | US | disclosed |
| CN-115381824-B | Use of cyclin-dependent kinase 9 inhibitors | 石药集团中奇制药技术（石家庄）有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-115381823-B | Application of cyclin-dependent kinase 9 inhibitor | 石药集团中奇制药技术（石家庄）有限公司 | 2024-11-05 | — | — | CN | disclosed |
| CN-114787142-B | Compounds as cyclin dependent kinase 9 inhibitors and uses thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2024-08-02 | — | — | CN | disclosed |
| EP-3377473-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3583096-B1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2009055077-A1 | TROPANE COMPOUNDS | EXELIXIS, INC. (US) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009034388-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008074035-A1 | HCV PROTEASE INHIBITORS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-1877366-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | Chroma Therapeutics Limited (GB) | 2008-01-16 | — | — | EP | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | CENGENT THERAPEUTICS (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2006117548-A1 | HYDROXAMIC ACID DERVICATIVES AS INHIBITORS OF HDAC ENZYMATIC ACTIVITY | CHROMA THERAPEUTICS LTD (GB) | 2006-11-09 | — | — | WO | disclosed |
| WO-2005027856-A2 | INHIBITORS OF ANTHRAX LETHAL FACTOR | CENGENT THERAPEUTICS (US) | 2005-03-31 | — | — | WO | disclosed |
| EP-0512352-B1 | Substituted carboxylic acid derivatives | HOFFMANN LA ROCHE (CH) | 1996-03-27 | — | — | EP | disclosed |
| US-5344843-A | Carnitine acryltransferase enzyme inhibitors as antiischemic agents and for cardiovascular disorders | HOFFMAN-LA ROCHE INC. (US) | 1994-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250114374-A1 | BCL-2 INHIBITORS | BCL2, BCL2L1, BCL2L10 | CTSS 1544/4885CTSK 505/4885FOLH1 4818/4885 |
| US-20070197577-A1 | Inhibitors of anthrax lethal factor | APAF1, ANTXR2, LITAF | CTSS 596/4885CTSK 306/4885FOLH1 3243/4885 |
| US-20240025849-A1 | INHIBITORS OF NO PRODUCTION | NOS2, NOS1, NOS3 | CTSS 2305/4885CTSK 2681/4885FOLH1 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.